---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-25-000023"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:02:44.958063+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027

## Summary
- Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.
- Preliminary cash, equivalents & marketable securities of $212.5M as of March 31, 2025.
- Discontinued GALLOP (lupus), AMpLify (AML) trials & preclinical research to focus on CB-010 & CB-011.
- Estimated restructuring costs of $2.5-3.5M, primarily severance and trial wind-down.
- Cash runway extended one year to H2 2027; CB-010 & CB-011 data readouts planned for H2 2025.

## SEC filing metadata
- accession: 0001619856-25-000023
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/0001619856-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985625000023/crbu-20250424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-25-000023
- JSON: https://secwatch.observer/filing/0001619856-25-000023.json
- Plain text: https://secwatch.observer/filing/0001619856-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.